Q&A Interview with Fast Growing Biotech Products Company UV Flu Technologies (OTCBB: UVFT)

December 1, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com ) - www.InvestorIdeas.com and its leading Biotech investor portal release a Q&A with biotech company UV Flu Technologies, Inc. (OTCBB: UVFT). Mr. John J. Lennon, President & CEO, discusses recent developments with the company's air purifying technology, ViraTech UV-400.

Interview:
Q: Investorideas.com
To give investors an introduction, UV Flu Technologies Inc. (OTCBB: UVFT) develops and manufactures technologies within the Indoor Air Quality (IAQ) industry sector, with your primary product, the ViraTech™ UV-400 model that purifies indoor air by killing bacteria, including superbugs such as NDM-1.
As global awareness increases for the need for better air and water quality technology, your company is aggressively marketing its technology to both consumers and industry. Can you give some hi- lights of what's in the pipeline?
A: Our Company is building a brand. The inadequacy of previous entrants in the air-purifier marketplace makes our job all the more important. Companies in the past, and present, continue to sell millions of air purifiers, with technology that just doesn't work in the residential marketplace. Our products are designed to work with almost no maintenance required. As long as the green light is on, our UV-400 is killing contaminants! We are designing a model specifically for the residential marketplace that we believe will be a category killer! It will have all the killing capabilities of our UV-400, at a lower price point. It will have the capability to kill, and trap, will be the most attractive air purifier in the world, and will have independent, FDA/EPA lab certified test results to support every claim. It will also have 3-4 times the coverage of a typical HEPA based unit, at the same price.
We will also purchase higher volume models to extend our lines on the commercial side.
Q: Investorideas.com
According to your website," Independent EPA and FDA certified laboratory testing confirms the system kills airborne bacteria at rates ranging from 99.2% to more than 99.99% on a first-pass basis. In actual operation multiple passes through the unit will occur, producing average removal rates that far exceed 99.2%." How does this compare to competition in terms of cost and efficiency?
A: Interestingly enough, there are very few units in the world today that actually kill contaminants. Over 95% of air purifiers on the market today capture, but don't kill contaminants. They rely on electrostatic, or HEPA filter technology, which captures, but doesn't kill particulates. All of these products, if filters or plates are not replaced or cleaned on a regular basis, can produce air that is actually dirtier than leaving the unit off. The filters become a “petrie" dish, where bacterial or viral colonies can grow in the filter.
The UV-400 has a kill chamber, which uses Germicidal UV light to kill organic contaminants. Independent lab tests have verified that the killing ability is almost identical, whether it is bacteria, or viruses. The unit can cover a space of up to 7-900 sq ft, while still passing the air 3X per hour. Competing HEPA or electrostatic products can cover 150-200 sq ft, when the filter is clean-less when the filter is dirty. It would typically take 4 HEPA filters to cover the same space. These products typically need $100-150 annually in new filters, as well.
Q: Investorideas.com
The company has completed the design of its second product, a smaller, lower cost version of the ViraTech™ UV-400. Can you give us some insight into the markets and applications for it?
A: One residential electrostatic air purifier product sold 3 million units at $400 apiece, before it was pulled from the market, due to its inability to clean the air. We think there is an international market potential for our product of several hundred thousand units per year. The market would be geared to the market for bedrooms, apartments, hotel room, and small offices, where price points, and space coverage requirements are lower.
Q: Investorideas.com
According to a recent report by Global Industry Analysts, Inc., demand for air filters in developing countries will outpace growth in mature markets such as US, European, and Japan. By 2015, China will supplant Japan to become the second largest market for air filter equipment behind United States. What are the company's plans to participate in the global market?
A: The Company already has the international markets in its sights. Air quality in developing markets, including China, is considerably worse than in this country. The Company has begun shipping units to Europe, which suffers from epidemic rates of HAI's, or hospital associated infections, like MRSA, and plans on having distribution to China by mid-year 2011.
About UV Flu Technologies, Inc. (OTCBB: UVFT).
UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available.
Investors can view the full company profile for UV Flu Technologies, Inc. (UVFT.OB) at: http://www.investorideas.com/CO/UVFT/
Research Report by Michael Williams, Biotech Stock Pick: www.biotechstockpick.com
Find out more about UV Flu Technologies, Inc. (UVFT.OB) at: www.uvflutech.com
Request news and stock alerts from UV Flu Technologies, Inc. (UVFT.OB)
http://www.investorideas.com/Resources/Newsletter.asp
Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
About InvestorIdeas.com :
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal : www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
For Additional Information about Investorideas.com Biotech portals:
800-665-0411

Investor Video; BioSante (NASDAQ: BPAX) Presentation at Cancer Immunotherapy Conference BioSante Pharmaceutical’s President and CEO Discusses BioSante Portfolio of Cancer Vaccines

Point Roberts, WA, LINCOLNSHIRE, Ill - November 30, 2010 (Investorideas.com Newswire) Invest orideas.com, an investor research portal specialized in sector investing including biotech and pharma stocks, features an investor video featuring showcase company BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).

The video, featuring Stephen M. Simes, President and CEO, was recorded during "Cancer Immunotherapy: A Long Awaited Reality", a conference hosted by BioBusiness.TV and MD Becker Partners on October 21st, 2010, at the New York Academy of Medicine. Mr. Simes discusses the GVAX wide portfolio of cancer vaccines.
Mr. Simes reports, "There are fifteen BioSante cancer vaccine Phase I and Phase II studies ongoing in different cancers."
Watch BioSante's segment on Cancer Vaccines for the Cancer Immunotherapy Conference the following link is provided: http://www.biobusiness.tv/report-on-location/biosante-presentation-at-cancer-immunotherapy-conference-1548/
Highlights from the Cancer Vaccines Product Page:
Read the Full info at: http://www.biosantepharma.com/Cancer-Vaccines.php
BioSante Pharmaceuticals Inc. is developing a pipeline of Immunotherapies (cancer vaccines). BioSante's cancer vaccines use cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immunostimulant. The cells then are irradiated to prevent further cell division; however the cells remain metabolically active.
Currently, BioSante's Cancer Vaccines are in various Phase I and Phase II cancer clinical trials and may represent the widest portfolio (cancer types) of cancer vaccines in development. Studies are conducted primarily at Johns Hopkins Cancer Center and are sponsored/funded by The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, various philanthropies, foundations and the National Cancer Institute
Cancer Types Being Studied:

• Leukemia
• Chronic Myeloid Leukemia (CML)
• Acute Myeloid Leukemia (AML)
• Pancreatic Cancer
• Breast Cancer
• Multiple Myeloma
• Melanoma
• Colorectal
• Prostate Cancer

Chronic Myeloid Leukemia (CML) — Results of a Phase II clinical trial
Of 19 patients treated with GVAX CML, 7 had complete remission.

• Gleevec was taken for at least one year (range 13-53 months) pre-vaccine and then GVAX CML was administered while the patients remained on a stable dose of Gleevec.
• 19 patients enrolled (median of 72 months of follow-up)
• 13 patients (8 of whom had increasing disease burden before vaccination): the number of remaining cancer cells declined
• 12 patients reached their lowest levels of residual cancer cells to date following vaccination
• 7 patients had complete remission

"We want to get rid of every last cancer cell in the body, and using cancer vaccines may be a good way to mop up residual disease," said lead investigator Hyam Levitsky, M.D., professor of oncology, medicine and urology at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland.
Acute Myeloid Leukemia (AML) — Results of Phase II
Patients treated with GVAX had both a relapse-free survival and overall survival rate improvement of approximately 30% compared with the non-GVAX-treated subjects.

• GVAX AML was accompanied by immunotherapy-primed lymphocytes after autologous stem cell transplantation.
• 54 subjects enrolled
• 28 (52%) received a pre-transplantation GVAX AML dose
• 46 (85%) subjects achieved complete remission during the treatment period. Of these patients, the 3-year relapse-free survival (RFS) rate was:
  • 47.4% in non-GVAX treated patients
  • 61.8% in the GVAX-treated group
  • Overall survival (OS) rate in all subjects was 57.4%
  • Overall survival (OS) rate was 73.4% in the GVAX-treated group
  • In summary, patients treated with GVAX had both a relapse-free survival and overall survival rate improvement of approximately 30% compared with the non-GVAX-treated subjects

Read more on BioSante's Cancer Vaccines and clinical trial info at: http://www.biosantepharma.com/Cancer-Vaccines.php
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal : www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer:
The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411 cvanzant@investorideas.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Urgent Health Threat from Airborne Viruses; How UV Flu Technologies, Inc. (OTCBB: UVFT innovative new air purification technology is more effective than filtering

Point Roberts WA - November 30, 2010 – www.Investorideas.com, an investor research portal
specialized in sector investing, issues biotech stocks commentary by Lisa Springer, CFA, equity
research analyst and financial writer. The report entitled,’ Urgent Health Threat from Airborne
Viruses ‘, features UV Flu Technologies, Inc. (OTCBB: UVFT) and its air purification technology.

Urgent Health Threat from Airborne Viruses

Lisa Springer, CFA, Equity research analyst and financial writer

Stocks in this report: UV Flu Technologies, Inc. (OTCBB: UVFT), Pall Corp (NYSE:PLL),
Donaldson Company (NYSE:DCI)

There is an urgent health threat deadlier than the H1N1 pandemic on the rise, yet few Americans
are aware of it. The threat comes from infections acquired while in the hospital. According to a
recent government study, America’s hospitals aren’t adequately protecting patients from these
potentially deadly infections. A 2009 report by the US Health and Human Services department
found little progress has been made over the past decade in eliminating hospital-acquired
infections and urged Congress to take action.

As many as 98,000 Americans die each year from medical errors and preventable infections are
a major contributor to the problem. Ten years ago, the Institute of Medicine launched a campaign
to stamp out hospital-acquired infections, but the success of their initiatives has been minimal.
The latest report showed three of five major types of hospital-acquired infections have actually
become more prevalent, one showed no progress and only one declined. Bloodstream infections,
which are considered the most serious and potentially fatal, rose 8.0 percent. There was also
a sizable 3.6 percent increase in the incidence of urinary tract infections. While generally
responsive to antibiotics, urinary tract infections increase hospitalization time and costs. Overall,
the incidence of common hospital-acquired infections was up 1.6 percent.

Media coverage of hospital-acquired infections, the swine flu pandemic and antibiotic resistant
superbugs is raising consumer awareness and spurring government agencies and businesses
to take action to safeguard public health. Demand for products that prevent the spread of
airborne illnesses is rising exponentially. The swine flu pandemic created a $7 billion windfall for
vaccine manufacturers, according to the Wall Street Journal, and a bonanza for makers of hand
sanitizers, who experienced a 129% jump in shipments during last year’s flu season.
This heightened awareness is also spreading to the nearly $8 billion annual market for indoor air
quality products. These products improve air quality in commercial buildings, hospitals, schools
and homes by removing airborne pathogens. Scientific studies show poor indoor air quality is
a major reason for the spread of infectious disease. According to the Environmental Protection
Agency, the air inside buildings where people spend 90% of their time now poses a greater threat
than outdoor air.

Most air quality systems use a simple filter (either standard or HEPA) to trap pathogens.
Well-known filter device manufacturers include Pall Corp (NYSE:PLL), Donaldson Company
(NYSE:DCI) and Millipore, which was recently acquired by Merck KGaA. A relative newcomer
to this market, UV Flu Technologies, Inc. (OTCBB: UVFT), has developed an innovative new air
purification technology that is more effective than filtering. This technology disinfects indoor air
by deactivating allergens and killing airborne pathogens, including bacteria, viruses and mold.
UV Flu Technologies flagship product, the ViraTech UV-400, uses high intensity germicidal UV
radiation inside a killing chamber to trap and destroy harmful microbes. Extensive independent
testing by EPA and FDA certified laboratories confirms UV Flu Technologies system captures and

kills airborne bacteria and viruses at rates exceeding 99.2% on a first pass basis. The technology
is so effective that UV Flu Technologies was able to secure a Class II medical listing enabling it to
market its product as a medical device.

Since introducing its flagship device less than one year ago, UV Flu Technologies has sold
units to multiple sports teams, hospitals, restaurants and other commercial customers. Two
professional hockey teams (including the renowned Boston Bruins) and numerous college
teams have installed ViraTech UV-400 units in their locker rooms. In addition, the company has
installed units at two major hospitals and has units being evaluated by a large nursing home
chain. Hospitality customers such as The Seagate Hotel and Spa in Delray Beach, Florida, the
Boston Harbor Hotel and Boston’s XV Beacon Hotel have installed ViraTech UV-400 units and
one of the nation's largest 5 star hotels is evaluating the unit for its operations. Tests of units
are also underway with one of the largest hotel and restaurant suppliers in the Northeast. In
addition, "Clean Air for Everyone," a non-profit promoting clean air for schools and non-profits
across America recently selected the ViraTech UV-400 as its lead product for national rollout.

UV Flu Technologies plans to expand its product line and distribution capabilities by acquiring
a major US manufacturer of high quality air purification equipment. The company hopes to
complete the merger this year. Included in the agreement is a patented product line, national
distribution network, and installed base of several thousand units across 1,000 unique facilities
nationwide. UVFT President Jack Lennon notes that the expanded product line will make the
company more attractive to large US distributors and improve its visibility in the hospital, hotel
and casino markets. UV Flu Technologies is also expanding its sales channels by adding three
new distributors. The new distributors are Emerald Medical Service, a supplier of medical
equipment serving the Washington, DC area; UV Air, a supplier to government, schools,
and hotels in Massachusetts and Factory-Direct Green, a distributor servicing over 400 hotel
customers in California.

Lisa Springer, CFA -Bio and disclaimer: http://www.investorideas.com/About/Lisa-Springer-CFA/

The author, Lisa Springer, was compensated for writing this article and doesn't own shares of any
of the companies mentioned in this article.

About UV Flu Technologies, Inc. (OTCBB: UVFT)

UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology
products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over
$7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-
intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to
destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also
reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone,
benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables
UV Flu Technologies to market the product as a medical device. For more information, visit:
www.uvflutech.com. For sales: www.puravair.com.
Read the forward looking statements disclaimer on all company press releases and company
website.

UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

UV Flu Technologies, Inc.

Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com

About InvestorIdeas.com:

InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including biotech stocks.
Research more biotech stocks at the Biotech stocks Directory:
http://www.investorideas.com/BIS/Stock_List.asp

Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc.,
(three thousand per month) Lisa Springer CFA- Investorideas compensated three hundred fifty
for article. Investorideas.com is a third party publisher of news and research .Our sites do not
make recommendations, but offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. This site is currently compensated by featured companies, news
submissions and online advertising.

Contact Investorideas.com
cvanzant@investorideas.com 800 665 0411

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Highlights 2010 Operations as ViraTech UV-400 Is Selected as Product of Choice by National Clean Air Foundation

CENTERVILLE, MA � November 29, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company"), manufacturers of innovative air purification technology, announced today that the Company has been informed by one of its distributors, INE Global, of Boston, Mass, that "Clean Air for Everyone," a national non-profit promoting clean air for schools and non-profits around the Country, has selected the ViraTech UV-400 as the lead product to be distributed throughout America.

"This product can help our schools, and the children within them," said John Pappas, spokesperson for 'Clean Air for Everyone.' "There are thousands of schools, homeless shelters, and Aids clinics around the country, that suffer through horrific air quality, due to the lack of funding to correct or improve the situation. The UV-400 kills the bacteria, odors, VOCs, and other organic contaminants that cause sickness, respiratory problems, and allergies that make our children ill."
The announcement of this news now positions UV Flu Technologies across a multitude of operational initiatives and industry segments including:
Sports and Athletics - Announced an order of UV-400 units in the locker room of the renowned Boston Bruins hockey team. "This is the second professional hockey team to put the UV-400 in their locker rooms, along with numerous colleges," noted Charles Gulteri President of New England Sports Sales (NESSI). "This could be one of the most important developments to college and professional sports in the last 20 years."
Healthcare and Medical - Units have been utilized in 2 major hospitals, and are currently being evaluated by a major nursing home chain. Units placed with the prestigious Miami Anatomical Research Center featuring 40 state-of-the art bio-skill lab stations in a hospital style setting.
Hospitality, Hotel & Spa - The Seagate Hotel and Spa in Delray Beach, Florida, the Boston Harbor Hotel, and Boston's XV Beacon Hotel utilize the ViraTech UV-400. "Providing this extra level of protection sets us apart from the competition," said William Sander, GM of the Seagate Hotel. UV Flu announced a new hospitality initiative branded ABC ROOMS, representing guest rooms and public areas treated for Allergens/Bacteria/and Contaminants. One of the nation's largest 5 star hotels is currently evaluating the unit for all areas of its operation.
European Market - Profiled in two editions (July and October) of the prestigious UK industry opinion and analysis publication "The Public Service Review" featuring the latest initiatives and projects on best practices affecting public sector initiatives worldwide. This announcement was followed almost immediately by a sales order with Paris based, Societe Nema Citizen, the largest distributor of Citizen Brand electronics in France, and a growing inventory of health and medical-related products sold throughout Western Europe.
Restaurants - The ViraTech UV-400 is undergoing testing supervised by one of the largest hotel and restaurant suppliers in the Northeast. The unit is being evaluated in the lounge, dining, and food prep areas of 3 notable NYC restaurants. The product's ability to reduce odors, VOCs, while killing bacteria and other contaminants, is drawing considerable attention in this segment.
Industrial and Commercial - UV Flu announced a Letter of Intent ("LOI") to acquire 100% of the ownership of a major US manufacturer of high quality industrial air purification equipment specializing in the medical and hospitality marketplace. The agreement includes a patented, trademarked product line, with dozens of national distributors and representatives, an extensive customer list, inventory, and all associated manufacturing equipment. The company's sales include an installed base of several thousand units in over 1000 unique facilities nationwide.
National Distribution Network - The Company added 3 new distributors including Emerald Medical Service, a supplier of medical equipment throughout the Washington, DC area, UV Air, a supplier to government, schools, and hotels in the Woburn, MA area, and Factory-Direct Green, a distributor servicing over 400 hotel customers in the Carlsbad, California area.
New Research - Received favorable preliminary test results from independent FDA and EPA certified test facilities that demonstrated the ViraTech UV-400 air purifier to be effective in the inactivation of a typical virus surrogate utilized as part of the test protocol. If advanced stage testing proves positive, this could be a momentous step forward in the further development of the product as a Medical Device.
Television - UV Flu Technologies invites everyone to visit the Company website (www.uvflutech.com) to view an informative, seasonal video presented by the producers of the TV show, "Designing Spaces" which highlights the features and benefits of the UV-400 especially during the Holiday Season.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Air Purifier Stocks Close-Up; UV Flu Technologies (OTCBB: UVFT), Lennox (NYSE: LII), Sharp (TYO: 6753), SEUNG CHANG (KOSDAQ: 080470.KQ)

Point Roberts WA - November 26 (Investorideas.com Newswire) Investorideas.com, a leader in sector research for independent investors, reports on publicly traded stocks in the air purifier market.

Sector snapshot – stocks in the air purifier market

• Clean & Science (KOSDAQ: 045520.KQ)
• Lennox International, Inc. (NYSE: LII )
• SEUNG CHANG (KOSDAQ: 080470.KQ)
• Sharp (TYO: 6753)
• Sharper Image Corp. (SHRPQ.PK)
• UV Flu Technologies, Inc. (OTCBB: UVFT)

Plasmacluster air purifier is designed in Japan by Sharp, a global leader in microelectronics. Sharp's shares are listed on Tokyo, Osaka, Nagoya, Fukuoka and Sapporo in Japan, securities code 6753.
According to an article in air-purifier-power.com, "The purifier market is rapidly consolidating, with many small players disappearing."
http://www.air-purifier-power.com/sharp-air-purifier.html
Lennox International, Inc. (NYSE: LII ) residential Heating & Cooling manufactures and markets a full line of home heating and cooling equipment: furnaces, air conditioners, heat pumps, fireplaces and hearth products, as well as a variety of accessories to improve indoor air quality including humidifiers and electronic air cleaners.
Clean & Science Co., Ltd. (KOSDAQ: 045520.KQ) is a Korea-based manufacturer engaged in the provision of value-added materials for filters. The Company provides its products under three main categories: automotive filter media, which is used as core component in air, oil and fuel filters; industrial filter media, which is used in the gas turbine air filters, cutting filters, dry-cleaning filters and compressor filters, and melt blown, which is used in ventilation and air conditioning filters, high efficiency particulate air (HEPA) filters, medical equipment, water purifiers, industrial masks and others. The Company also manufactures filters such as air cleaner filters, air conditioner filters and gas turbines filters.
Recent Air Purifier Stock News;
UV Flu Technologies (OTCBB: UVFT) Identifies New Prospects for UV-400 Air Purifier With Rising Health Concerns Within Hospitality Market Segments
CENTERVILLE, MA - November 17, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company"), announced today that the Company is expanding its focus within the Hospitality industry to newly identified areas suffering from serious health concerns for both customers and employees alike. Commencing immediately, the Company will direct efforts to provide its UV-400 air quality solution targeting the restaurant and spa sectors.
Restaurants generally prove vulnerable to poor indoor air quality, particularly with respect to the use of cleaning solvents in the dining room and bar areas, as well as the possibility for odors, mold and mildew that can plague food preparation areas. Full news: http://www.investorideas.com/CO/UVFT/news/11171.asp
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available.
Investors can view the full company profile for UV Flu Technologies, Inc. (UVFT.OB) at: http://www.investorideas.com/CO/UVFT/
Research Report by Michael Williams, Biotech Stock Pick: www.biotechstockpick.com
Find out more about UV Flu Technologies, Inc. (UVFT.OB) at: www.uvflutech.com
Request news and stock alerts from UV Flu Technologies, Inc. (UVFT.OB)
http://www.investorideas.com/Resources/Newsletter.asp
Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.

Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory:
http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) sells virus technology to Cold Genesys

LINCOLNSHIRE, Ill. - November 17, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) said Wednesday it sold rights to develop and commercialize its oncolytic virus technology to Cold Genesys Inc. for $95,000 and a nearly 20 percent ownership stake in that company.

BioSante, based in Lincolnshire, Ill., also can receive future milestone and royalty payments.
Oncolytic virus therapy uses a virus that causes colds to attack cancer cells. The adenoviruses are engineered to replicate inside targeted cancer cells to kill them and leave healthy cells largely unharmed.
Technology sold to Cold Genesys includes CG0070, an adenovirus that finished early-stage clinical testing for the treatment of superficial bladder cancer.
Cold Genesys, based in Newport Beach, Calif., is a privately-funded specialty pharmaceutical company that currently is focused on finding treatments for bladder cancer.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
For more information, please contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Identifies New Prospects for UV-400 Air Purifier With Rising Health Concerns Within Hospitality Market Segments

CENTERVILLE, MA � November 17, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company"), announced today that the Company is expanding its focus within the Hospitality industry to newly identified areas suffering from serious health concerns for both customers and employees alike. Commencing immediately, the Company will direct efforts to provide its UV-400 air quality solution targeting the restaurant and spa sectors.

Restaurants generally prove vulnerable to poor indoor air quality, particularly with respect to the use of cleaning solvents in the dining room and bar areas, as well as the possibility for odors, mold and mildew that can plague food preparation areas.
In the personal grooming arena, Spas and Salons across the Country have demonstrated increasing evidence of illnesses affecting employees, customers, and even children due to the presence of Volatile Organic Compounds ("VOC") emitted by a variety of hair, nail and other personal grooming treatments, in many instances with little or no air purification whatsoever provided.
"There are serious ramifications building across the Country due to the lack of education on how damaging these contaminants are to the long term health of the people that are breathing them on a regular basis," said Jack Lennon, President of UV Flu Technologies. "We are contacted on a weekly basis by parents, as well as workers and customers, who have experienced symptoms of illness themselves, or whose children have experienced negative effects while certain treatments were underway with no air purification in evidence, or with non-functioning air purifiers being used."
"A particularly troubling aspect is that many of these individuals breathing these VOC's are at young ages critical to the development of their heart and lungs," continues Mr. Lennon, "Some of these popular hair treatments have been shown recently to contain up to 20% formaldehyde, while acetone and benzene are being used for nails. These contaminants are known carcinogens, and salons who are not addressing the concerns of their employees and customers are not only facing a loss of business, but the risk of litigation, as well as potential legislation."
Mr. Lennon continues, "Regarding the several-hundred thousand restaurants in this country, we believe that up to one in four restaurants suffers to a degree from odors caused by cleaning solvents, and in such a competitive marketplace it doesn't take much to adversely affect a business in an area that has already been severely hurt by the decline of the domestic economy. If people smell chemicals when they dine out, they may leave, or choose not to return... and in many instances it's a subliminal decision. In the food prep area there are many opportunities due principally to moisture that can affect the build-up of odors, mold and mildew. Good food preparation procedures alone can't prevent these types of air quality issues which ultimately could not only hurt the reputation of the business, but in extreme cases, cause its closure."
"Our air purifier, the ViraTech UV-400, reduces all types of odors and Volatile Organic Compounds, while also killing bacteria and other contaminants. The unit could potentially pay for itself in its first day of operation in many instances. We think from the standpoint of return on investment, as well an obligation to keep their employees and customers healthy and safe, this is a must-buy product," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp